Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: big changes at Biogen; Paxlovid still a work in progress; Farxiga goes stellar; Moderna hints at M&A; and a chat with Roche Pharma India’s CEO on rare diseases.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 6 May 2022, including: big changes at Biogen, Inc.; Paxlovid still a work in progress; Farxiga goes stellar; Moderna, Inc. hints at M&A; and a chat with Roche Holding AG Pharma India’s CEO on rare diseases.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus" - Scrip, 3 May, 2022.)
(Also see "Pfizer On Paxlovid: "There's Still A Long Way To Go"" - Scrip, 3 May, 2022.)
(Also see "AstraZeneca’s Farxiga Flies Across $1bn Barrier" - Scrip, 29 Apr, 2022.)
(Also see "Moderna Teases M&A Interest As Pandemic Expected To Wind Down" - Scrip, 4 May, 2022.)
(Also see "It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support" - Scrip, 2 May, 2022.)